2026 Bugatti Tourbillon Sounds Menacing in New Audio Clip
The 2026 sounds like one mean machine in a new audio clip shared by the head of the company.
The successor to the is the first car from to use a V-16 engine, now that the brand retired its famous W-16 format.
Bugatti plans to build just 250 Tourbillons, with production scheduled to start next year. Pricing for the new model starts at $4.6 million.
New audio of the 2026 Bugatti Tourbillon makes us think the 1775-horsepower hypercar starts each day with a healthy bowl of nuts and bolts. A brief Instagram video shared by Bugatti CEO Mate Rimac announces the Tourbillon with an aggressive bark while revving followed by a series of acceleration videos on track that sound simply phenomenal. For anyone worried about Bugatti's adoption of hybridization, you can put those fears to rest.
According to Rimac, the audio is representative of what the production car's exhaust will sound like. "Hopefully we can keep it soft-limiter free!" the CEO wrote in his post. We couldn't agree more, as the 8.3-liter V-16 Cosworth-developed engine is rated up to 9000 rpm. With the trio of electric motors added in, the Tourbillon's powerplant produces a combined 1775 horsepower. Take the electrons away, and the combustion mill still puts out an incredible 986 horsepower and 664 pound-feet of torque.
"What a car," Rimac said on the post. "I don't think we understand yet what we have built. This will be one for the history books." He added "Here's to the team! Keep pushing - the world is waiting!" We sure are, Mate. We sure are.
Bugatti will only build 250 Tourbillons, with production slated to begin next year. The price befits the promised performance, with window stickers expected to start around $4,600,000.
You Might Also Like
Car and Driver's 10 Best Cars through the Decades
How to Buy or Lease a New Car
Lightning Lap Legends: Chevrolet Camaro vs. Ford Mustang!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
A&W Restaurants Announces Strategic Franchise Expansion in Columbia, South Carolina and Neighboring Cities
Legacy brand known for its all-American food identifies Columbia and surrounding cities as prime markets for continued growth LEXINGTON, Ky., June 12, 2025 /PRNewswire/ -- A&W Restaurants, an all-American QSR with more than 105 years of experience in business and serving communities, announced today its strategic plans to expand the brand's presence across Columbia, South Carolina and into the neighboring cities, including Darlington. A&W's expansion into Colombia presents aspiring local entrepreneurs with the opportunity to grow alongside a heritage brand and bring a proven business model into their own communities. Columbia, South Carolina, is a prime location for business expansion, driving strong economic performance and GDP growth compared to other states nationally. This economic shift and increased population growth have fueled steady demand for housing, retail and dining throughout Columbia and surrounding areas. The growing population is naturally creating opportunities for businesses to serve this growing customer base. A&W's expansion plans include various new territories for single and multiple-unit development and provide up to 100 new job opportunities per location. This dynamic market presents an ideal opportunity for franchise owners and customers who value familiar, high-quality dining options. "A&W Restaurants has become part of communities across the country by serving classic all-American food and offering a welcoming, hometown experience," said Betsy Schmandt, CEO and president of A&W Restaurants. "At A&W, we're committed to helping franchise owners build something lasting, something they can be proud to pass down for generations. We see tremendous potential in Columbia and its neighboring cities, where passionate, community-driven entrepreneurs can help us continue our legacy of bringing people together." A&W restaurant is actively expanding its footprint in South Carolina with plans to open three locations over the next few years. The brand first arrived in the state when local franchisees opened their Rock Hill location in 2023. The city of Darlington welcomed its first A&W on June 4, 2025. With more than 850 locations worldwide, A&W's expansion reflects the company's commitment to partner with local entrepreneurs who share the brand's values of quality, service and community. A&W Restaurants is seeking potential franchise partners in Columbia, South Carolina, who are passionate about their communities and care about delivering exceptional service to guests with the support of an iconic family brand. Join a trusted franchise with more than 105 years of experience backed by a team with a proven track record for support, growth and innovation in helping businesses become generational legacies and community staples. The minimum investment level to own a franchise is $300K in liquid assets and a total net worth of $700K. To learn more about franchising with A&W Restaurants, visit our franchise website here. About A&W Restaurants: A&W Restaurants, one of the world's best-known and most beloved quick-service brands, is experiencing a dramatic revival as more Americans discover – or rediscover – its famous Root Beer and high-quality All American Food® favorites. Based on the original 1919 recipe, A&W's signature Root Beer is made fresh in each restaurant with real cane sugar, water, and a proprietary blend of herbs, bark, spices, and berries and served in a frosty mug. Founded over 100 years ago, A&W Restaurants has over 850 locations in 35 U.S. states and Asia, of which over 600 are single-brand A&Ws and 230 are co-branded with KFC or Long John Silver's. View original content to download multimedia: SOURCE A&W Restaurants Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
The Verge
3 hours ago
- The Verge
Snapchat's latest subscription tier will get you ‘hundreds' of lenses
Snapchat has launched a new subscription tier that offers access to a wider selection of lenses and augmented-reality experiences. The Lens Plus subscription costs $8.99 per month and will include lenses made by Snapchat and 'select' creators to start, such as an exclusive AI-powered video lens and a Bitmoji game lens. Along with access to 'hundreds' of different lenses, Lens Plus comes with the same benefits as a $3.99 / month Snapchat Plus subscription, which includes access to early and exclusive features, like the ability to use wallpapers with chats and Bitmoji backgrounds. This week, Snap announced that it plans to start selling its AR glasses, Specs, to the public in 2026. Snap CEO Steven Spiegel told my colleague Alex Heath that he believes lenses, which currently have 400,000 developers building them, will make Specs stand out from other AR glasses.
Yahoo
4 hours ago
- Yahoo
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) ('Rakovina' or the 'Company'), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that members of its executive team will attend the 2025 BIO International Convention, taking place June 16th – 19th in Boston, Massachusetts. Rakovina Therapeutics' management will participate in one-on-one partnering meetings throughout the conference with leading global pharmaceutical and biotechnology companies. The Company will showcase its pipeline of novel DNA damage response (DDR) inhibitors, including drug candidates discovered through its proprietary AI-driven platforms—Deep Docking and Variational AI's generative technology. These collaborations have produced promising compounds with potential applications in DDR-targeted oncology therapies, including candidates capable of penetrating the blood-brain barrier and addressing significant unmet medical needs in the treatment of cancer. KT-3000 Series The KT-3000 series is a novel class of dual-function small molecule inhibitors combining PARP and histone deacetylase (HDAC) inhibition in a single agent. Published pre-clinical data demonstrate that lead candidates for the kt-3000 series retain anti-tumor activity in cancers that are resistant to treatment with FDA-approved PARP inhibitors. The KT-3000 program presents an attractive partnering opportunity for companies seeking to expand their oncology portfolios with multi-functional agents that can be developed across a range of solid tumor indications. Rakovina is actively exploring collaborations to accelerate development and broaden the clinical utility of this program. KT-2000AI Series The KT-2000 series features highly selective PARP1 inhibitors designed to penetrate the blood-brain-barrier, addressing a critical unmet need in the treatment of primary and metastatic brain tumors. The Company previously announced that it had used its proprietary AI algorithm to screen billions of potential drug candidates to identify potential best-in-class lead candidates. By targeting PARP1 specifically—while sparing PARP2—the KT-2000 compounds are anticipated to deliver potent anti-tumor activity with an improved safety profile. The program is well positioned for strategic partnerships focused on advancing therapies for glioblastoma and other CNS-involved cancers, where few targeted options exist. KT-5000AI Series The KT-5000 series focuses on highly selective ATR inhibitors, a key target in the DNA damage response pathway. ATR inhibition has emerged as a promising strategy to exploit tumor vulnerabilities in cancers. Rakovina's AD-derived KT-5000 candidates are engineered for optimal selectivity and tolerability, positioning them for combination use with other DDR-targeted agents or standard-of-care therapies. The program represents a significant opportunity to address a wide range of solid tumors with high unmet medical need. 'The Rakovina Therapeutics team has advanced multiple programs from discovery to pre-clinical validation in our laboratories at the University of British Columbia. We look forward to engaging with potential partners who share our vision of accelerating breakthrough therapies through the integration of artificial intelligence and oncology expertise,' said Jeffrey Bacha, Executive Chairman. 'BIO provides an opportunity to both continue and initiate strategic discussions to drive long-term value through collaboration.' Rakovina's platform has already attracted interest from multiple pharmaceutical companies seeking differentiated assets and AI-powered discovery capabilities. The Company anticipates that upcoming milestones—including lead optimization data and new target nominations—will further enhance its strategic positioning. For more information or to schedule a meeting with Rakovina Therapeutics management at BIO, please contact: Michelle Seltenrich, Director, Corporate Development – About BIO International Convention The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. In a time of remarkable discovery and progress, the biotechnology industry stands at the forefront of a revolution changing how we live, heal, and care. From pioneering treatments offering hope to millions, to sustainable agricultural innovations to feed a growing population, or environmental breakthroughs securing our future, biotech drives positive change faster than ever. This progress is not just a change but a promise for a brighter future. The world is ready. For more information: About Rakovina Therapeutics Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Notice Regarding Rakovina Therapeutics Forward-Looking Statements: This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as 'plans,' 'is expected,' 'expects,' 'scheduled,' 'intends,' 'contemplates,' 'anticipates,' 'believes,' 'proposes' or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results 'may,' 'could,' 'would,' 'might,' or 'will' be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition. Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company's most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company's profile page at For Further Information Contact:Michelle Seltenrich, BSc MBADirector, Corporate DevelopmentIR@ in to access your portfolio
